Services Market News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 3,
"returned": 3,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "485e4737-1c4f-4fcf-abac-6230a29edcbe",
"title": "Earnings call: Acurx Pharmaceuticals Reports Positive Phase IIb Results By Investing.com",
"description": "Earnings call: Acurx Pharmaceuticals Reports Positive Phase IIb Results",
"keywords": "",
"snippet": "Published Mar 18, 2024 07:16PM ET\n\n© Reuters.\n\nACXP -4.78% Add to/Remove from Watchlist\n\nAcurx Pharmaceuticals, Inc. (ACXP) has reported significant progress i...",
"url": "https://www.investing.com/news/stock-market-news/earnings-call-acurx-pharmaceuticals-reports-positive-phase-iib-results-93CH-3343068",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPECBE0OL_L.jpg",
"language": "en",
"published_at": "2024-03-18T23:16:30.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "CDI",
"name": "CDI Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Services",
"match_score": 11.23661,
"sentiment_score": 0.567344,
"highlights": [
{
"highlight": "(ACXP) has reported significant progress in its latest earnings call, particularly with its lead antibiotic candidate, ibezapolstat, for C. difficile infection (<em>CDI</em>). The company announced the successful completion of its Phase IIb clinical trial, which was terminated early due to its success and absence of safety concerns.",
"sentiment": 0.9313,
"highlighted_in": "main_text"
},
{
"highlight": "Key Takeaways\n\nAcurx completed enrollment in a Phase IIb clinical trial for ibezapolstat, which showed a high clinical cure rate for <em>CDI</em>.\n\nThe trial was ended early due to its success and no safety concerns were reported.\n\nAcurx is preparing for Phase III clinical trials and has received FDA Fast Track designation.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "On October 2, 2023, we ended enrollment in our Phase IIb clinical trial of ibezapolstat or IBEZ, our lead antibiotic candidate for the treatment of patients with C. difficile infection or <em>CDI</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "On January 17, 2024, we announced positive comparative microbiology and microbiome data for the ibezapolstat in <em>CDI</em> patients from the Phase IIb clinical trial segment.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "It is a very exciting time and really it's the final step to commercialize ibezapolstat for patients in need of a promising new antibiotic with a novel bactericidal mechanism of action to treat <em>CDI</em>, and many of you will remember that approximately 30,000 people die each year in the U.S. alone from <em>CDI</em> and the annual incidence is more than about 500,000",
"sentiment": 0.6444,
"highlighted_in": "main_text"
},
{
"highlight": "We'll also be including several high enrolling trial sites from the fast enrolling Summit Phase III <em>CDI</em> trial, which was conducted during the height of COVID-19.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "In addition to global scope of the program compared to Phase II and the strength of our Phase II data, the Phase III protocol will allow more flexibility for inclusion and exclusion criteria as a standard for <em>CDI</em> pivotal registration trials. So we anticipate faster enrollment.",
"sentiment": 0.6771,
"highlighted_in": "main_text"
},
{
"highlight": "I think, I have got a great rear view mirror and a clear vision to say that we have a winner here for patients with <em>CDI</em> and in general for better public health as well as for our shareholders. Thanks for letting me comment, Dave.\n\nRobert Shawah: Thank you, Bob. Melissa, we're now ready to go to Q&A.",
"sentiment": 0.9732,
"highlighted_in": "main_text"
},
{
"highlight": "So this is not severe <em>CDI</em>, but a little bit more than moderate according to the IDSA criteria for patient entry into a trial in the study. So we've already submitted a framework to the FDA in the meeting package. It's very straightforward. I'd even say a higher percentage that they've said at 90%. We're pretty much there with the design.",
"sentiment": 0.6741,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "41d923c5-84f8-4352-ade0-a45699c759a8",
"title": "2 ASX shares I can’t ignore: CSL and RMD",
"description": "The CSL Ltd (ASX:CSL) share price is lower 0.8% since the start of the 2024. The Resmed CDI (ASX:RMD) share price is also in focus.",
"keywords": "",
"snippet": "CSL share price\n\nThe ASX:CSL ) share price is lower 0.8% since the start of the 2024. Meanwhile, the ASX:RMD ) share price is 21% away from its 52-week high.\n\nC...",
"url": "https://www.raskmedia.com.au/2024/03/19/2-asx-shares-i-cant-ignore-csl-and-rmd-5/",
"image_url": "https://www.raskmedia.com.au/wp-content/uploads/2023/11/asx-share-market.jpg",
"language": "en",
"published_at": "2024-03-18T18:02:17.000000Z",
"source": "raskmedia.com.au",
"relevance_score": null,
"entities": [
{
"symbol": "CDI",
"name": "CDI Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Services",
"match_score": 12.324121,
"sentiment_score": 0.743,
"highlights": [
{
"highlight": "Our websites explain Discounted Cash Flow (DCF), Dividend Discount Models (DDM), and many different ways to value a share, like Resmed <em>CDI</em>.",
"sentiment": 0.743,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "808f6291-fb3d-46e1-bbe8-4553b9173a0c",
"title": "Tech talk: WAAAX off, task on",
"description": "Ron Shamgar of TAMIM Asset Management explains why the unity of WiseTech Global Ltd (ASX: WTC), Afterpay Ltd (ASX: APT), Altium Ltd (ASX: ALU), Appen Ltd (ASX: APX), and Xero Ltd (ASX: XRO), formerly called \"the WAAAX group\" ended; and the takeover of TASK Group Holdings Limited (ASX: TSK) started.",
"keywords": "",
"snippet": "Ron Shamgar of TAMIM Asset Management explains why the unity of WiseTech Global Ltd (ASX: WTC), Afterpay Ltd (ASX: APT), Altium Ltd (ASX: ALU), Appen Ltd (ASX: ...",
"url": "https://www.raskmedia.com.au/2024/03/18/tech-talk-waaax-off-task-on-ron-shamgar-tamim/",
"image_url": "https://www.raskmedia.com.au/wp-content/uploads/2024/03/tech-talk-waaax-off-task-on-ron-shamgar-tamim.jpg",
"language": "en",
"published_at": "2024-03-18T05:29:47.000000Z",
"source": "raskmedia.com.au",
"relevance_score": null,
"entities": [
{
"symbol": "CDI",
"name": "CDI Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Services",
"match_score": 12.006565,
"sentiment_score": -0.7783,
"highlights": [
{
"highlight": "Afterpay’s acquisition by Block Inc (NYSE: SQ) and Block Inc <em>CDI</em> (ASX: SQ2) for an astounding $39 billion arguably signalled the top of the tech bull market when it was acquired by Block.\n\nBlock share price\n\nAltium now faces a takeover of its own and Appen grapples with a downturn, leaving WiseTech and Xero as stalwarts.",
"sentiment": -0.7783,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "Services",
"total_documents": 3,
"sentiment_avg": 0.17734799782435098
}
]
}
Other details
Entity count
- 18,055